ScholarIQanswers from OpenAlex & ORCID
Richard L. Schilsky
ResearcherPublications, citations & collaboration network
Richard L. Schilsky is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard L. Schilsky have?
ScholarIQindexed works
Richard L. Schilsky has 558 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard L. Schilsky have?
ScholarIQcitation count
Richard L. Schilsky has 40,158 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard L. Schilsky?
ScholarIQh-index
Richard L. Schilsky has an h-index of 93 in OpenAlex.
What is the i10-index of Richard L. Schilsky?
ScholarIQi10-index
Richard L. Schilsky has an i10-index of 320 in OpenAlex.
What is the ORCID of Richard L. Schilsky?
ScholarIQorcid
The ORCID for Richard L. Schilsky is on the source record.
What is the OpenAlex record for Richard L. Schilsky?
ScholarIQopenalex
The OpenAlex for Richard L. Schilsky is on the source record.
What are the most-cited papers on Richard L. Schilsky?
ScholarIQmost cited works
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford A. Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert B. Livingston, James N. Ingle, Edith A. Perez, John T. Carpenter, David D. Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey S. Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker, Geoffrey R. Oxnard, Carolyn C. Compton, Maximilian Diehn, Patricia A. Hurley, Alexander J. Lazar, Neal Lindeman, Christina M. Lockwood, Alex J. Rai, Richard L. Schilsky, Apostolia M. Tsimberidou, Patricia Vasalos, Brooke L. Billman, Thomas K. Oliver, Suanna S. Bruinooge, Daniel F. Hayes, Nicholas C. Turner
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper, Nancy E. Davidson, Dana S. Wollins, Courtney Tyne, Douglas W. Blayney, Diane Blum, Adam P. Dicker, Patricia A. Ganz, J. Russell Hoverman, Robert M. Langdon, Gary H. Lyman, Neal J. Meropol, Therese M. Mulvey, Lee N. Newcomer, Jeffrey Peppercorn, Blasé N. Polite, Derek Raghavan, Gregory Rossi, Leonard B. Saltz, Deborah Schrag, Thomas J. Smith, Peter Paul Yu, Clifford A. Hudis, Richard L. Schilsky
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert I. Hurwitz, Federico Innocenti, Mary F. Mulcahy, Eileen M. O’Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg